Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Seiko Hirono

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3054-1038; OpenAlex author ID A5021237761. Sources: OpenAlex.

Their work

Papers
38 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
131
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 4 papers · 2017: 5 papers · 2018: 2 papers · 2019: 1 paper · 2020: 6 papers · 2021: 3 papers · 2022: 3 papers · 2023: 4 papers · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 38

  1. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  2. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… Co-author DOI 10.1097/sla.0000000000006900↗
  3. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  4. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  5. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Co-author DOI 10.1002/ags3.12712↗
  6. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  7. Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.ejso.2023.06.012↗
  8. Autophagy Inhibition Increased Sensitivity of Pancreatic Cancer Cells to Carbon Ion Radiotherapy. Co-author DOI 10.33594/000000639↗
  9. Reply to: Correspondence reading "Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces loco… Co-author DOI 10.1016/j.ejso.2021.11.008↗
  10. Supervised Exercise Therapy and Adjuvant Chemotherapy for Pancreatic Cancer: A Prospective, Single-Arm, Phase II Open-Label, Nonrandomized, Historically Contro… Co-author DOI 10.1097/xcs.0000000000000408↗
  11. Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by… Co-author DOI 10.1245/s10434-021-10985-0↗
  12. Advances in immunotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.944↗
  13. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreat… Co-author DOI 10.1016/j.ejso.2021.06.005↗
  14. Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline rese… Co-author DOI 10.1111/den.13926↗
  15. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). Co-author DOI 10.1007/s00423-020-01857-4↗
  16. Fully covered self-expandable metal stent with an anti-migration system vs plastic stent for distal biliary obstruction caused by borderline resectable pancrea… Co-author DOI 10.1097/md.0000000000018718↗
  17. [Surgical treatment for resectable pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.117.302↗
  18. Preoperative In-Hospital Rehabilitation Improves Physical Function in Patients with Pancreatic Cancer Scheduled for Surgery. Co-author DOI 10.1620/tjem.251.279↗
  19. Preoperative Scoring System to Predict Prognosis in Patients Who Undergo Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14399↗
  20. Utility of Contrast-Enhanced Harmonic Endoscopic Ultrasonography for Early Diagnosis of Small Pancreatic Cancer. Co-author DOI 10.3390/diagnostics10010023↗
  21. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. First author DOI 10.1016/j.surg.2018.12.015↗
  22. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomize… Co-author DOI 10.1186/s13063-018-3002-z↗
  23. Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer. Co-author DOI 10.18632/oncotarget.25837↗
  24. Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12013↗
  25. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Co-author DOI 10.1002/ijc.30510↗
  26. Current advance and future foresight of surgical treatment for pancreatic cancer. Co-author DOI 10.11405/nisshoshi.114.607↗
  27. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multi… Co-author DOI 10.1159/000478660↗
  28. Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer. First author DOI 10.21873/anticanres.11389↗
  29. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Co-author DOI 10.1007/s00280-016-3121-8↗
  30. Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: A multicenter observational study. Co-author DOI 10.1016/j.surg.2016.02.032↗
  31. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Grou… Co-author DOI 10.1097/mpa.0000000000000579↗
  32. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement. Co-author DOI 10.1097/mpa.0000000000000634↗
  33. Tips and tricks of the surgical technique for borderline resectable pancreatic cancer: mesenteric approach and modified distal pancreatectomy with en-bloc celi… Co-author DOI 10.1002/jhbp.184↗
  34. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. Co-author DOI 10.1007/s11605-014-2637-7↗
  35. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.109↗
  36. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-013-2323-6↗
  37. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments:… Co-author DOI 10.1007/s00534-013-0616-0↗
  38. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. First author DOI 10.1111/j.1349-7006.2012.02214.x↗

Closest collaborators

The 25 strongest of 131 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroki Yamaue · 34 shared papers, 2012–2026 · strength 3.54
  2. Manabu Kawai · 28 shared papers, 2012–2026 · strength 2.58
  3. Yuji Kitahata · 19 shared papers, 2012–2026 · strength 2.06
  4. Ken‐ichi Okada · 22 shared papers, 2012–2023 · strength 1.98
  5. Motoki Miyazawa · 19 shared papers, 2012–2023 · strength 1.78
  6. Sohei Satoi · 11 shared papers, 2013–2026 · strength 0.90
  7. Michiaki Unno · 7 shared papers, 2015–2026 · strength 0.71
  8. Etsuro Hatano · 4 shared papers, 2023–2026 · strength 0.64
  9. Yuichi Nagakawa · 4 shared papers, 2018–2026 · strength 0.61
  10. Atsushi Shimizu · 8 shared papers, 2012–2023 · strength 0.58
  11. Keiko Kamei · 3 shared papers, 2024–2026 · strength 0.57
  12. Hideki Motobayashi · 3 shared papers, 2022–2026 · strength 0.54
  13. Masayuki Sho · 7 shared papers, 2013–2026 · strength 0.51
  14. Hidetoshi Eguchi · 5 shared papers, 2013–2026 · strength 0.49
  15. Ippei Matsumoto · 6 shared papers, 2015–2023 · strength 0.39
  16. Kenjiro Kimura · 2 shared papers, 2023–2026 · strength 0.37
  17. Hiromitsu Hayashi · 2 shared papers, 2023–2026 · strength 0.37
  18. Kenichiro Uemura · 4 shared papers, 2015–2026 · strength 0.36
  19. Amane Takahashi · 2 shared papers, 2024–2026 · strength 0.35
  20. Shintaro Yagi · 2 shared papers, 2024–2026 · strength 0.35
  21. Yusuke Sano · 2 shared papers, 2024–2026 · strength 0.35
  22. Naoto Gotohda · 2 shared papers, 2024–2026 · strength 0.35
  23. Makoto Ueno · 2 shared papers, 2024–2026 · strength 0.35
  24. Naoki Ikenaga · 2 shared papers, 2024–2026 · strength 0.35
  25. Akimasa Nakao · 3 shared papers, 2013–2026 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.